Search Results - "Henschen, Stephan"

Treatment of Classic Mid-Trimester Preterm Premature Rupture of Membranes (PPROM) with Oligo/Anhydramnion between 22 and 26 Weeks of Gestation by Means of Continuous Amnioinfusion: Protocol of a Randomized Multicentric Prospective Controlled TRIAL and Review of the Literature by Tchirikov, Michael, Haiduk, Christian, Tchirikov, Miriam, Riemer, Marcus, Bergner, Michael, Li, Weijing, Henschen, Stephan, Entezami, Michael, Wienke, Andreas, Seliger, Gregor

“…Background: The classic mid-trimester preterm premature rupture of membranes (PPROM) is defined as a rupture of the fetal membranes prior to 28 weeks of…”
Get full text

A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER + HER2 - Primary Breast Cancer by Robertson, John F R, Evans, Abigail, Henschen, Stephan, Kirwan, Cliona C, Jahan, Ali, Kenny, Laura M, Dixon, J Michael, Schmid, Peter, Kothari, Ashutosh, Mohamed, Omar, Fasching, Peter A, Cheung, Kwok-Leung, Wuerstlein, Rachel, Carroll, Danielle, Klinowska, Teresa, Lindemann, Justin P O, MacDonald, Alexander, Mather, Richard, Maudsley, Rhiannon, Moschetta, Michele, Nikolaou, Myria, Roudier, Martine P, Sarvotham, Tinnu, Schiavon, Gaia, Zhou, Diansong, Zhou, Li, Harbeck, Nadia

“…Fulvestrant, the first-in-class selective estrogen receptor (ER) degrader (SERD), is clinically effective in patients with ER breast cancer, but it has…”
Get full text

Abstract P6-04-01: A pre-surgical, window of opportunity study comparing the novel oral SERD AZD9496 with fulvestrant in patients with newly diagnosed ER+ HER2- primary breast cancer by Robertson, John FR, Evans, Abigail, Henschen, Stephan, Kirwan, Cliona, Jahan, Ali, Kenny, Laura, Dixon, J. Michael, Schmid, Peter, Kothari, Ashutosh, Mohamed, Omar, Fasching, Peter A, Cheung, Kwok-Leung, Wuerstlein, Rachel, Carroll, Danielle, Klinowska, Teresa, Lindemann, Justin PO, MacDonald, Alexander, Mather, Richard, Maudsley, Rhiannon, Moschetta, Michele, Nikolaou, Myria, Roudier, Martine P, Sarvotham, Tinnu, Schiavon, Gaia, Zhou, Diansong, Zhou, Li, Harbeck, Nadia

“…Background: Estrogen receptor positive (ER+) breast cancer is routinely treated with endocrine therapies targeting the ER axis. However, primary and secondary…”
Get full text

Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer—results from the GeparQuattro study (GBG 40) by von Minckwitz, Gunter, Darb-Esfahani, Silvia, Loibl, Sibylle, Huober, Jens, Tesch, Hans, Solbach, Christine, Holms, Frank, Eidtmann, Holger, Dietrich, Klaus, Just, Marianne, Clemens, Michael R., Hanusch, Claus, Schrader, Iris, Henschen, Stephan, Hoffmann, Gerald, Tiemann, Katharina, Diebold, Kurt, Untch, Michael, Denkert, Carsten

“…Adjacent ductal carcinoma in situ (DCIS) is found in approximately 45% of invasive ductal carcinomas (IDC) of the breast. Pure DCIS overexpresses HER2 in…”
Get full text

Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study by Wallwiener, Markus, Nabieva, Naiba, Feisst, Manuel, Fehm, Tanja, de Waal, Johann, Rezai, Mahdi, Baier, Bernd, Baake, Gerold, Kolberg, Hans-Christian, Guggenberger, Martin, Warm, Mathias, Harbeck, Nadia, Wuerstlein, Rachel, Deuker, Jörg-Uwe, Dall, Peter, Richter, Barbara, Wachsmann, Grischa, Brucker, Cosima, Siebers, Jan Willem, Popovic, Milos, Kuhn, Thomas, Wolf, Christopher, Vollert, Hans-Walter, Breitbach, Georg-Peter, Janni, Wolfgang, Landthaler, Robert, Kohls, Andreas, Rezek, Daniela, Noesselt, Thomas, Fischer, Gunnar, Henschen, Stephan, Praetz, Thomas, Heyl, Volker, Kühn, Thorsten, Krauss, Thomas, Thomssen, Christoph, Hohn, Andre, Tesch, Hans, Mundhenke, Christoph, Hein, Alexander, Rauh, Claudia, Bayer, Christian M, Schmidt, Katja, Belleville, Erik, Brucker, Sara Y, Hadji, Peyman, Beckmann, Matthias W, Wallwiener, Diethelm, Kümmel, Sherko, Hartkopf, Andreas, Fasching, Peter A

“…Treatment of postmenopausal, hormone receptor-positive metastatic breast cancer (MBC) patients varies despite clear therapy guidelines, favoring endocrine…”
Get full text

Hormone receptor discordance between local and central pathology with RT-PCR analysis: Results from multicenter Phase III WSG-PlanB trial by Von Schumann, Raquel, Gluz, Oleg, Nitz, Ulrike, Clemens, Michael, Luebbe, Kristina, Aktas, Bahriye, Just, Marianne, Noesselt, Thomas, Henschen, Stephan, Hackmann, John, Lorenz-Salehi, Fatemeh, Freese, Kristin, Svedman, Christer, Kates, Ronald E., Kreipe, Hans Heinrich, Harbeck, Nadia, Liedtke, Cornelia

“…Abstract only…”
Get full text

Prospective comparison of recurrence score and independent central pathology assessment of prognostic tools in early breast cancer (BC): Focus on HER2, ER, PR, Ki-67 results from the phase III WSG-Plan B trial by Gluz, Oleg, Kreipe, Hans Heinrich, Christgen, Matthias, Degenhardt, Tom, Kates, Ronald E., Liedtke, Cornelia, Shak, Steven, Clemens, Michael R., Salem, Marwa, Markmann, Susanne, Liedtke, Bernd, Aktas, Bahriye, Henschen, Stephan, Pollmanns, Anke, Krabisch, Petra, Uleer, Christoph, Augustin, Doris, Thomssen, Christoph, Nitz, Ulrike, Harbeck, Nadia

“…Abstract only 552 Background: Use of multi-gene real-time PCR (RT-PCR) based assays e.g. Recurrence Score (RS) and single markers (grade, uPA/PAI-1, ER/PR,…”
Get full text

Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study by Gaß, Paul, Fasching, Peter A., Fehm, Tanja, de Waal, Johann, Rezai, Mahdi, Baier, Bernd, Baake, Gerold, Kolberg, Hans-Christian, Guggenberger, Martin, Warm, Mathias, Harbeck, Nadia, Wuerstlein, Rachel, Deuker, Jörg-Uwe, Dall, Peter, Richter, Barbara, Wachsmann, Grischa, Brucker, Cosima, Siebers, Jan W., Fersis, Nikos, Kuhn, Thomas, Wolf, Christopher, Vollert, Hans-Walter, Breitbach, Georg-Peter, Janni, Wolfgang, Landthaler, Robert, Kohls, Andreas, Rezek, Daniela, Noesselt, Thomas, Fischer, Gunnar, Henschen, Stephan, Praetz, Thomas, Heyl, Volker, Kühn, Thorsten, Krauss, Thomas, Thomssen, Christoph, Hohn, Andre, Tesch, Hans, Mundhenke, Christoph, Hein, Alexander, Rauh, Claudia, Bayer, Christian M., Jacob, Adib, Schmidt, Katja, Belleville, Erik, Hadji, Peyman, Brucker, Sara Y., Beckmann, Matthias W., Wallwiener, Diethelm, Kümmel, Sherko, Löhberg, Christian R.

“…Background: Decision-making for or against neoadjuvant or adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive breast cancer does…”
Get full text

Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial by Witzel, Isabell, Loibl, Sibylle, von Minckwitz, Gunter, Mundhenke, Christoph, Huober, Jens, Hanusch, Claus, Henschen, Stephan, Hauschild, Maik, Lantzsch, Tilmann, Tesch, Hans, Latos, Kunibert, Just, Marianne, Hilfrich, Jörn, Barinoff, Jana, Eulenburg, Christine zu, Roller, Marc, Untch, Michael, Müller, Volkmar

“…In the context of neoadjuvant therapy (NT) for breast cancer patients, different targeted therapy approaches are currently evaluated in clinical trials. Serum…”
Get full text

Determination of circulating blood volume by measurement of indocyanine green dye in hemolysate: a preliminary study by Busse, M W, Zisowsky, S, Henschen, S, Panning, B, Reilmann, L

“…In 8 emergency care patients blood volume was determined using Cr5I labelled erythrocytes and indocyanine green (ICG). Prior to measurement of ICG in blood…”
Get more information